# A Study of Sotatercept in Participants With PAH WHO FC III or FC IV at High Risk of Mortality (MK-7962-006/ZENITH)

Study · id `cardio:ct-nct04896008` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT04896008](<https://clinicaltrials.gov/study/NCT04896008>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT04896008

Browse, organ or system: Heart; Blood vessels  
Browse, condition area: Coronary and vascular disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 173 participants.

## Technical summary

Registry record NCT04896008. Randomized; triple masking; primary purpose treatment. Start 2021-12-01 (actual); primary completion 2024-07-26 (actual). Results posted on 2025-08-22.

## Key facts

- Design: Interventional study; randomized; triple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 173 participants (enrolled count; ClinicalTrials.gov record NCT04896008, source copy `cardio:ctgov-nct04896008-2026-05-29`, retrieved 2026-10-31)
- Started: 2021-12-01 (actual) (ClinicalTrials.gov record NCT04896008, source copy `cardio:ctgov-nct04896008-2026-05-29`, retrieved 2026-10-31)
- Primary completion: 2024-07-26 (actual) (ClinicalTrials.gov record NCT04896008, source copy `cardio:ctgov-nct04896008-2026-05-29`, retrieved 2026-10-31)
- Completion: 2025-02-18 (actual) (ClinicalTrials.gov record NCT04896008, source copy `cardio:ctgov-nct04896008-2026-05-29`, retrieved 2026-10-31)
- Results first posted: 2025-08-22 (ClinicalTrials.gov record NCT04896008, source copy `cardio:ctgov-nct04896008-2026-05-29`, retrieved 2026-10-31)
- Countries: United States; Australia; Belgium; Canada; France; Germany; Israel; Italy; Mexico; Netherlands; Spain; United Kingdom (ClinicalTrials.gov record NCT04896008, source copy `cardio:ctgov-nct04896008-2026-05-29`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct04896008-2026-05-29`, retrieved 2026-10-31)

## The registry's words

- Brief title: A Study of Sotatercept in Participants With PAH WHO FC III or FC IV at High Risk of Mortality (MK-7962-006/ZENITH)
- Acronym: ZENITH
- Condition: Pulmonary Arterial Hypertension
- Intervention (Drug): Sotatercept
- Intervention (Other): Placebo
- Lead sponsor: Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Pulmonary arterial hypertension (`cardio:pulmonary-arterial-hypertension`)
- Registry condition terms include this condition: Pulmonary hypertension (`cardio:pulmonary-hypertension`)
- Registry lists this organization as the lead sponsor: Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA (`cardio:org-acceleron-pharma-inc-a-wholly-owned-subsidiary-of-merck-co-341e98`)

### Other papers using this trial's data

- Registry lists this paper as a reference of type result; PubMed dates it on or after the trial start and types it as a trial report, neither its types nor its title mark it as a protocol, a review or a comment, the paper names no other trial in place of this one, and PubMed shows no retraction or expression of concern; it is not marked as the trial's main report: Sotatercept in Patients with Pulmonary Arterial Hypertension at High Risk for Death (`cardio:pubmed-40167274`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: 3d56028400919e0115ea97cb4650433dfdb3e792d5f146befe7aeae579cf021e
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
